泓博医药(股票代码：301230)成立于2007年，总部位于上海，致力于为全球医药客户提供新药研发和商业化生产一站式综合服务，涵盖药物发现、制药工艺的研究开发以及原料药、中间体的商业化生产等领域。目前，公司拥有超过22000平方米研发实验室(37000平方米临床前新药研发基地在建中）以及60000平方米生产基地，研发技术人员占比超63%。在16年的征途中,泓博医药通过特有的“CRO”和“CDMO业务模式,构建了全方位综合性技术平台,为国内外客户的新药研发提供了有力支撑。
PharmaResources（StockCode：301230.SZ）was founded in 2007 and is headquartered in Shanghai. The company is committed to providing comprehensive services for global pharmaceutical clients, including new drug research and development and commercial production, covering areas such as drug discovery, pharmaceutical process research and development, as well as commercial production of active pharmaceutical ingredients and intermediates. Currently, the company has over 22,000 square meters of R&D laboratories (with a 37,000 square meter preclinical new drug R&D base under construction) and a 60,000 square meter production base. R&D technical personnel account for over 63% of the workforce. Over the course of its 16-year journey, PharmaResources has established a comprehensive technical platform through its unique 'CRO' and 'CDMO' business models, providing strong support for the new drug development of domestic and international clients.